These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 27923629)

  • 41. [Detection of epidermal growth factor receptor gene mutations in non-small cell lung cancers by real-time polymerase chain reaction using scorpion amplification refractory mutation system].
    Zhang J; Liang ZY; Zeng X; Wu SF; Gao J; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2008 May; 37(5):294-9. PubMed ID: 18956645
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
    De Pas T; Toffalorio F; Manzotti M; Fumagalli C; Spitaleri G; Catania C; Delmonte A; Giovannini M; Spaggiari L; de Braud F; Barberis M
    J Thorac Oncol; 2011 Nov; 6(11):1895-901. PubMed ID: 21841502
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer.
    Jiang B; Liu F; Yang L; Zhang W; Yuan H; Wang J; Huang G
    J Int Med Res; 2011; 39(4):1392-401. PubMed ID: 21986139
    [TBL] [Abstract][Full Text] [Related]  

  • 45. RBX1 expression is an unfavorable prognostic factor in patients with non-small cell lung cancer.
    Xing R; Chen KB; Xuan Y; Feng C; Xue M; Zeng YC
    Surg Oncol; 2016 Sep; 25(3):147-51. PubMed ID: 27566015
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analysis of CEA expression and EGFR mutation status in non-small cell lung cancers.
    Yang ZM; Ding XP; Pen L; Mei L; Liu T
    Asian Pac J Cancer Prev; 2014; 15(8):3451-5. PubMed ID: 24870738
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Analysis of EGFR mutations in 176 cases of non-small cell lung cancer].
    Dong QG; Han BH; Huang JS; Yang LM; Huang J; Zhao CY; Lu LQ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):686-90. PubMed ID: 17274376
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration.
    Nakajima T; Yasufuku K; Suzuki M; Hiroshima K; Kubo R; Mohammed S; Miyagi Y; Matsukuma S; Sekine Y; Fujisawa T
    Chest; 2007 Aug; 132(2):597-602. PubMed ID: 17573511
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer.
    Horiike A; Kimura H; Nishio K; Ohyanagi F; Satoh Y; Okumura S; Ishikawa Y; Nakagawa K; Horai T; Nishio M
    Chest; 2007 Jun; 131(6):1628-34. PubMed ID: 17565015
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
    Chu H; Zhong C; Xue G; Liang X; Wang J; Liu Y; Zhao S; Zhou Q; Bi J
    Oncol Rep; 2013 Nov; 30(5):2311-5. PubMed ID: 24002698
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epidermal growth factor receptor mutations in 510 Finnish non--small-cell lung cancer patients.
    Mäki-Nevala S; Rönty M; Morel M; Gomez M; Dawson Z; Sarhadi VK; Telaranta-Keerie A; Knuuttila A; Knuutila S
    J Thorac Oncol; 2014 Jun; 9(6):886-91. PubMed ID: 24828666
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI).
    Tseng YH; Hung HY; Sung YC; Tseng YC; Lee YC; Whang-Peng J; Chen YM
    J Chemother; 2016; 28(1):50-8. PubMed ID: 25976428
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
    Kimura H; Kasahara K; Kawaishi M; Kunitoh H; Tamura T; Holloway B; Nishio K
    Clin Cancer Res; 2006 Jul; 12(13):3915-21. PubMed ID: 16818687
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Influence of mutations in epidermal growth factor receptor gene on growth, metastasis and survival rate of non-small cell lung carcinoma].
    Yin XW; Jiang XT; Yuan YT; Du YP
    Zhonghua Yi Xue Za Zhi; 2010 Jul; 90(26):1808-12. PubMed ID: 20979823
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
    Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
    J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
    Kosaka T; Yatabe Y; Onozato R; Kuwano H; Mitsudomi T
    J Thorac Oncol; 2009 Jan; 4(1):22-9. PubMed ID: 19096302
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer.
    Ikeda T; Nakamura Y; Yamaguchi H; Tomonaga N; Doi S; Nakatomi K; Iida T; Motoshima K; Mizoguchi K; Nagayasu T; Tsukamoto K; Kohno S
    Clin Lung Cancer; 2012 Sep; 13(5):369-74. PubMed ID: 22410386
    [TBL] [Abstract][Full Text] [Related]  

  • 58. EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy.
    Chang YL; Wu CT; Shih JY; Lee YC
    Ann Surg Oncol; 2011 Oct; 18(10):2952-60. PubMed ID: 21409490
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
    Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
    J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.
    Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
    Anticancer Res; 2013 Apr; 33(4):1705-11. PubMed ID: 23564819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.